Case histories / Synairgen

Synairgen

Synairgen

A specialist respiratory biotech company whose primary focus is developing our investigative inhaled IFN-β for the treatment of severe viral lung infections.

At the height of the pandemic, Niche's rapid manuscript writing helped Synairgen publish their landmark interferon beta COVID-19 trial results, unlocking the company's largest ever fundraising round.

01 Summary

Synairgen used Niche's expertise in the writing of manuscripts to quickly and efficiently develop high-quality documents for submission to relevant journals. Niche's high standards of manuscript preparation and ability to adapt to different journal requirements ensured successful publication. Services included:

  • General editorial and medical writing support
  • Drafting key manuscripts
  • Guiding the team on dissemination strategy
02 Project background

Synairgen is a clinical-stage biopharmaceutical company based in the UK, focused on developing novel treatments for respiratory diseases. Founded as a spin-out from the University of Southampton in 2003, the company leverages its expertise in respiratory science and drug development to address unmet medical needs, particularly in conditions like asthma and chronic obstructive pulmonary disease. Synairgen's lead product, SNG001, is an inhaled formulation of interferon beta, aimed at treating viral respiratory infections, including COVID-19. The company has garnered attention for its innovative approach to leveraging existing antiviral therapies to improve patient outcomes in respiratory illnesses. With a commitment to advancing research and development in respiratory health, Synairgen continues to explore new avenues for therapeutic interventions.

03 Delivery

Niche was approached by Synairgen for support in their interferon beta treatment (SNG001) for COVID-19 and COPD during the pandemic. Niche provided support in the development of manuscripts and regulatory documentation for the Phase II data in COVID-19 and COPD, the revolutionary approach to dosing in the home environment and the initiation of a Phase III trial. The Niche team’s expertise in quick and efficient manuscript writing helped Synairgen stay at the forefront of the wave of treating COVID-19.

Niche's work helped Synairgen get recognised by investors worldwide, which at the time, led to the largest fund raising drive ever experienced by the company. This allowed Synairgen the best opportunity to continue testing their product in further clinical trials. Based on the successful Phase II trial with SNG001 for which Niche contributed massively, Synairgen has since been able to initiate a Phase III trial in 17 countries.

“

We thank Niche for the enormous contribution they made to moving the Synairgen interferon beta treatment for COVID-19 forwards. We recognise and hugely appreciate the tenacity, adaptiveness dexterity and sheer hard work.

Richard Marsden, CEOSynairgen plc ★★★★★

Facing a similar challenge?

Tell us where your programme is. We will show you how we can help.

© 2025 Niche.org.uk     All rights reserved

HomePrivacy policy Corporate Social Responsibility